Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial.
Toxic Optic Neuropathy, Treatment, Methylprednisolone
About this trial
This is an interventional treatment trial for Toxic Optic Neuropathy focused on measuring Toxic Optic Neuropathy, Methylprednisolone, Erythropoietin
Eligibility Criteria
Inclusion Criteria: Both genres. Age between 18 and 75 years. Clinical diagnosis of toxic optic neuropathy (afferent pupillary defect, acquired dyschromatopsia, visual loss and bilateral prechiasmatic field defect). Exposure with a temporal relationship of less than two weeks to a known toxicant for the function of the optic nerve. Up to 21 days from symptom onset. Informed consent signature. Exclusion Criteria: History of previous optic neuropathy. History of additional ophthalmological or neurological pathology that has caused permanent visual loss. History of previous treatment with intravenous methylprednisolone or some other experimental treatment since the onset of symptoms. Poorly controlled diabetes mellitus. Poorly controlled systemic arterial hypertension. Hemoglobin >16 mg/dL Patients with a history of thromboembolic event. Patients with a history of coronary heart disease, myocardial infarction or cerebral vascular event. Pregnancy or lactation.
Sites / Locations
- Jorge Cárdenas BelaunzaránRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Experimental group
Control group
The patients will receive intravenous erythropoietin - 10,000 IU every 24 hours for 5 days.
The patients will receive intravenous methylprednisolone - 1 g every 24 hours for 5 days.